Return to Listing

2 result(s) for

PI Name Protocol # Title
Michael Heinrich STUDY00017418 A Phase 3, Multi-Center, Open-Label Randomized Study of Oral Asciminib Versus Bosutinib in Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or more Tyrosine Kinase Inhibitors
Michael Heinrich STUDY00019801 [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
For more information:
Call: 503-494-1080